

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, RM 200 ABC**

June 26, 2013

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for April 17, 2013 meeting (pages 3-9; Tab 1)
- IV. Secretary's report (page 11; Tab 2)
- V. Old Business
 - A. Proposed educational newsletter for Type2 diabetes treatment options (pages 13-16; Tab 3)
 - B. Mental Health Update....Dr. Linda Gochfeld
- VI. New Business
 - A. Protocols review (Tab 4) (abbreviations (page 17)
 1. Modafinil (Provigil[®]) (pages 19-21)
 2. Atypical antipsychotics (pages 22-24)
 3. Omega-3-Acid ethyl esters (page 25)
 4. NSAIDs (Cox-2 Inhibitor) (pages 26-28)
- VII. Informational Highlights/Reports
 1. Molina Prior Authorization Report (pages 29-30; Tab 5)
 2. Summary of DURB Action Items (page 31; Tab 5)
 3. ACA non-billing provider by specialty (page 32; Tab 5)
 4. NJ HMO Reports 1st Quarter 2013 (pages 33-36 Tab 6)
 5. DHS and DHSS Programs Top Drugs Report (pages 37-50; Tab 7)
 6. PACT information (page 51; Tab 8)
 7. Medication information (pages 53-57; Tab 9)
 - (a) FDA approves labels with lower doses for zolpidem sleep drugs
 - (b) FDA approves Breo[®] for COPD lung disease
 - (c) Researchers Debate Risks Of GLP-1-Based Therapies
 - (d) FDA Approves Nimodipine Oral Solution For Subarachnoid Hemorrhage